Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03452722

Enrollment

Registered

2018-03-02

Start date

2011-06-01

Completion date

2018-09-01

Last updated

2019-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Hypertensive Intracerebral Hemorrhage, Intraventricular Hemorrhage

Keywords

secondary brain injury, neuroinflammation

Brief summary

This study compares the neuroinflammatory response in patients with hypertensive ICH associated with IVH treated with intraventriculary applied rtPA, and the control group. The inflammatory mediator concentration is analyzed in local cerebrospinal liquor.

Interventions

DRUGintraventricual recombinant tissue plasminogen activator application

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Subjects with primary ICH with IVH * ICH score 2-4, , with origin of the hematoma in the basal ganglia and blood in the third and/or ventricle * Patient is not considered a surgical candidate by neurosurgery service

Exclusion criteria

* No history of diseases or drugs that affect the immunological system. * ICH score 1 and 5 * Current participation in another research drug treatment protocol * Previously known intracranial arteriovenous malformation or aneurysms * Intracerebral hematoma considered to be related to trauma * ICH is located in the pons * Blood in the subarachnoid space visualized on CT scan

Design outcomes

Primary

Measure	Time frame	Description
Cytokine concentration difference between two groups	Samples taken on day 0, day 1, day 3 and day 7.	Cytokine concentration measured from CSL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026